Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?

Purpose of Review Previous trials definitively established that lowering systolic blood pressure (BP) to 140 mmHg prevented heart failure (HF) exacerbations, but the potential benefits and risks of further BP reduction remain unclear due to a paucity of trial-based data. Recent Findings A recent sec...

Full description

Saved in:
Bibliographic Details
Published in:Current hypertension reports 2019-01, Vol.21 (1), p.9-9, Article 9
Main Authors: Upadhya, Bharathi, Stacey, Richard B., Kitzman, Dalane W.
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Cardiology
Family Medicine
General Practice
Heart Failure - prevention & control
Humans
Hypertension - drug therapy
Hypertension and the Heart (Bharathi Upadhya
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Diseases
Nephrology
Practice Guidelines as Topic
Primary Care Medicine
Randomized Controlled Trials as Topic
Risk Factors
Section Editor
Systole
Topical Collection on Hypertension and the Heart
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Previous trials definitively established that lowering systolic blood pressure (BP) to 140 mmHg prevented heart failure (HF) exacerbations, but the potential benefits and risks of further BP reduction remain unclear due to a paucity of trial-based data. Recent Findings A recent secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) found that in older, high-risk, non-diabetic participants with systolic hypertension, a BP treatment target
ISSN:1522-6417
1534-3111
DOI:10.1007/s11906-019-0913-3